Ariad Pharmaceuticals, Inc. (ARIA.W)
2.34USD
9 Feb 2010
$0.12 (+5.38%)
$2.34
--
$2.35
$2.18
2,415,364
1,257,294
$3.48
$0.97
ARIA.W
About
Overall
| Beta: | 1.05 |
| Market Cap (Mil.): | $256.25 |
| Shares Outstanding (Mil.): | 109.04 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| ARIA.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 1.96 | 3.76 |
| EPS (TTM): | 6.04 | -- | -- |
| ROI: | -151.72 | 0.92 | 2.30 |
| ROE: | -- | 1.27 | 2.82 |
UPDATE 1-Ariad early-stage cancer treatment shows promise
BANGALORE, Dec 7 (Reuters) - Ariad Pharmaceuticals Inc said interim data from an early-stage trial of its experimental cancer drug showed promise in treating patients with advanced blood cancers who are resistant to other therapies.
HEADLINE STOCKS-Some U.S. stocks on the move on Sept. 14
(Updates to add Bank of America, Morgan Stanley, Cooper/Goodyear, E*Trade, Eli Lilly, Biovail, Motorola, Xoma, GFI Group, First Solar, Auxilium, MGIC, Potash/Mosaic, SuccessFactors, Int'l Flavors, Avery Dennison, El Paso Electric, Cabelas, Coldwater)
UPDATE 2-Ariad says independent experts positive on cancer drug
* Interim analysis shows drug's safety profile consistent
HEADLINE STOCKS-Some U.S. stocks on the move on Sept. 14
(Updates to after the open, adds Chevron, Allegheny, Prospect Capital, Alcon, Ariad, Under Armour)
BEFORE THE BELL-Ariad Pharma up after comments on drug
NEW YORK, Sept 14 (Reuters) - Shares of Ariad Pharmaceuticals rose 13 percent to $2.96 in premarket trading on Monday, after the company said an independent committee of experts recommended that a late-stage trial of the company's experimental cancer treatment may continue.
UPDATE 3-Ariad Pharma says breast cancer drug shows promise
* Says observed 5 responses so far in breast cancer study
UPDATE 2-Ariad Pharma says cancer drug shows promise
* Says initial results show anti-cancer activity * Says drug shows activity in drug-resistant patients
Court rules for Lilly in patent fight with Ariad
WASHINGTON, April 3 (Reuters) - Eli Lilly did not infringe a patent owned by Ariad Pharmaceuticals when it made its Evista osteoporosis drug and Xigris sepsis treatment, a U.S. appeals court said on Friday.
US-RESEARCH/ (NON-S&P500)
Hewitt Associates Goldman Sachs Removes from Americas conviction sell list --------------------------------------------------------------- ------------ Intersil Corp JP Morgan Cuts to neutral from overweight --------------------------------------------------------------- ------------ Itron Inc JP Morgan Cuts to neutral from overweight --------------------------------------------------
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $-- | -- |
| Roche Holding Ltd. (ROG.VX) | CHF175.60 | -0.50 |
| Pfizer Inc. (PFE.N) | $-- | -- |
| Novartis AG (NOVN.VX) | CHF57.10 | +0.30 |
| GlaxoSmithKline plc (GSK.L) | £1,201.00 | -17.50 |
| Genentech, Inc. (DNA.N) | -- | -- |
| Eli Lilly & Co. (LLY.N) | $-- | -- |
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |
| AstraZeneca plc (AZN.L) | £2,820.00 | +4.50 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
